Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
A customer complaint was received indicating that the contrast phase of a p3t (personalize patient protocol technology) generated diagnostic protocol was skipped. during an analysis of the issue it was found that the protocol generated via p3t was not achievable by the stellant with certegra work station injector. the system informed the user via pop-up message "insufficient volume for programmed rate". the protocol on the injector head would then revert to the previous injection protocol but the display would continue to reflect the unachievable protocol to the technician. this could lead to a patient being injected with a different protocol than the technician intended. this situation only arises in stellant systems with certegra work stations with sofware version 100.60 or newer that have p3t software enabled.